Pfizer: agreement extended with CytoReason

(CercleFinance.com) - CytoReason announces an extension of its multi-year partnership with Pfizer.


Under the agreement, Pfizer will make a 20 million dollar equity investment, have licensing options for CytoReason's platform and disease models, and fund support, as part of a deal worth up to 110 million dollars.

Since the collaboration began in 2019, Pfizer has used CytoReason's biological models in its research to improve understanding of the immune system.

CytoReason's platform has provided Pfizer with multiple insights in research and development programs across over 20 diseases.

The new research agreement and investment will support the development of additional disease models and the creation of high resolution models, covering a number of therapeutic areas.



Copyright (c) 2022 CercleFinance.com. All rights reserved.